Tag:
Meda
Latest Headlines
Latest Headlines
Sources: Valeant eyes Meda for potential $4.4B deal
Valeant Pharmaceuticals is on the hunt again. The Canadian drugmaker has approached Swedish specialty pharma Meda about a deal, sources close to the companies are saying. With a current market value
Novartis sells off skin treatment for $420M
Novartis is selling the global rights to skin medicine Elidel to Sweden's Meda for $420 million, boosting Meda's position in dermatology. Report
BDSI, Meda, FDA talk about streamlining REMS for Onsolis
Raleigh, NC-based BioDelivery Sciences International has disclosed a July meeting with the FDA and Swedish pharmaceutical company Meda regarding the Onsolis cancer-pain treatment. The talks centered
BDSI gets $30M milestone
BioDelivery Sciences has pocketed a $30 million milestone payment from Meda as part of their licensing agreement for the commercialization of BEMA Fentanyl, a new pain patch for cancer patients. The
